NDLI: Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kelly, Ronan Joseph Sharon, Elad Hassan, Raffit
Description	Country affiliation: United States Author Affiliation: Kelly RJ ( Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.)
Abstract	The global burden of mesothelioma is expected to increase in the coming decades. As a result the development of more effective therapies with an emphasis on personalized treatments based on validated prognostic and predictive biomarkers is an essential requirement. Progress has been made in the last decade with the development of newer generation anti-folates leading to the current standard of care of pemetrexed and cisplatin in patients with unresectable disease. However, the median overall survival of patients with this combination treatment is only 12 months. There is no consensus regarding second line therapy for patients who have progressed or not responded to pemetrexed based therapies although gemcitabine in combination with a platinum compound or single agent vinorelbine is a reasonable option. The development of effective targeted agents that are active in mesothelioma has to date been disappointing. Strategies involving the addition of bevacizumab to pemetrexed and cisplatin in the frontline setting, the histone deacetylase inhibitor vorinostat as second line therapy and studies evaluating the utility of maintenance therapy in mesothelioma are all ongoing and appear promising. In addition clinical trials investigating immunotherapy and gene therapy in combination with chemotherapy could potentially improve the prognosis of patients with mesothelioma.
File Format	HTM / HTML
ISSN	01695002
e-ISSN	18728332
DOI	10.1016/j.lungcan.2011.04.014
Journal	Lung Cancer
Issue Number	3
Volume Number	73
Language	English
Publisher	Elsevier
Publisher Date	2011-09-01
Publisher Place	Ireland
Access Restriction	Open
Subject Keyword	Discipline Oncology Antineoplastic Combined Chemotherapy Protocols Therapeutic Use Immunotherapy Mesothelioma Genetics Immunology Therapy Antibodies, Monoclonal, Humanized Administration & Dosage Adverse Effects Bevacizumab Cisplatin Clinical Trials As Topic Deoxycytidine Analogs & Derivatives Drug Therapy Folic Acid Antagonists Genetic Therapy Glutamates Guanine Histone Deacetylase Inhibitors Hydroxamic Acids Pathology Molecular Targeted Therapy Pemetrexed Vascular Endothelial Growth Factor A Antagonists & Inhibitors Vinblastine Research Support, N.i.h., Intramural
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review.

Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma.

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.

Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

Similar Documents

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review.

Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma.

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.

Chemotherapy and targeted therapies for unresectable malignant mesothelioma.